CT vs PET Scans for Coronary Artery Disease

Overseen By Carlo De Cecco

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: Emory University

Must not be taking: Metformin

Disqualifiers: Pregnancy, Implanted devices, Psychiatric disorder, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: 1

47 Participants Needed

Trial Summary

What is the purpose of this trial?

The overall goal of this project is to compare the absolute quantification of myocardial perfusion done by using CT myocardial perfusion imaging (CT-MPI) and the coronary flow measured by using CT Fractional Flow Reserve analysis (CT-FFR) to the gold standard represented by PET myocardial perfusion imaging (PET-MPI).

Research Team

Carlo De Cecco, MD, PhD

Principal Investigator

Emory University

Eligibility Criteria

This trial is for individuals who need a CT scan to check for coronary artery disease and are willing to follow the study's procedures. They must not be pregnant, nursing, or have taken certain diabetes medications recently. People with implanted heart devices, severe allergies to contrast material used in scans, kidney issues, low blood pressure, or specific heart rhythm problems cannot participate.

Inclusion Criteria

Must be willing to comply with all clinical study procedures

Must provide written informed consent prior to any study-related procedures being performed

I am referred for a CT scan to check my heart's blood flow.

Exclusion Criteria

Pregnant or nursing females

Currently taking or has taken within 48 hours the following excluded medications: ActoPlus Met (Pioglitazone + metformin), Avandamet (Rosiglitazone + metformin), Fortamet (metformin), Glucovance (Glyburide +metformin), Glucophage (metformin), Glucophage extended-release (XR) (metformin), Glumetza (metformin), Janumet (Sitagliptin + metformin), Metformin, Metaglip (Glipizide + metformin), Riomet (metformin), Implanted rhythm devices (pacemaker, defibrillator), Acute psychiatric disorder, Unwilling to comply with the requirements of the protocol, Previously entered this study, Known hypersensitivity to iodinated contrast material, beta-blockers, or pharmaceutical stressors used in this study, Suffers from claustrophobia, Impaired renal function (GFR < 45 ml/min), Acute hypotension (<100 mm Hg systolic), 2nd or 3rd degree atrioventricular (AV) block

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Imaging and Analysis

Participants undergo PET-MPI, CT-MPI, and CT-FFR imaging for analysis of myocardial perfusion and coronary flow

1 day

1 visit (in-person)

Follow-up

Participants are monitored for safety and effectiveness after imaging procedures

4 weeks

Treatment Details

Interventions

• CT-FFR
• CT-MPI
• PET-MPI Protocol
• Regadenoson

Trial Overview The MATCH Investigation aims to compare two types of heart imaging tests: CT scans that measure blood flow and blockages in the heart arteries (CT-MPI and CT-FFR) against PET scans known as PET-MPI which is considered the gold standard.

Participant Groups

Group I: Three imaging techniques: PET-MPI, CT-MPI, and CT-FFR Experimental Treatment 4 Interventions

Participants referred for a clinical PET-MPI will also have CT-MPI and CT-FFR imaging performed for analysis of myocardial perfusion.

Who Is Running the Clinical Trial?

Emory University

Lead Sponsor

Trials

1,735

Recruited

2,605,000+

Siemens Medical Solutions

Industry Sponsor

Trials

26

Recruited

6,100+